Ger­man start­up jumps in­to the hot ra­dio­phar­ma space with a for­mer Ipsen com­pound as lead pro­gram

Ra­dio­phar­ma­ceu­ti­cals are con­tin­u­ing to be­come a hot top­ic in bio­phar­ma, with com­pa­nies such as Se­quoia, No­var­tis and Bris­tol My­ers Squibb look­ing to get in on the ac­tion. A new start­up launched Wednes­day is look­ing to catch the wave, start­ing with a team and as­sets from Ipsen.

Berlin-based Ariceum Ther­a­peu­tics has se­cured a €25 mil­lion ($26.7 mil­lion) Se­ries A to fur­ther de­vel­op its lead as­set and pro­pri­etary pep­tide de­riv­a­tive. Found­ed last year (and co-found­ed by EQT Life Sci­ences), Ariceum is head­ed by Man­fred Rüdi­ger, a vet­er­an of over 25 years in the bio­phar­ma world.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER